Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23351977 | 0.88 | ADAM17 (0.54) | ADAM17KMT2AMT-CO2ALOX5ALDH1A1 | |
| SCHEMBL18499737 | 0.86 | KMT2A (0.46) | ADAM17KMT2AMT-CO2ALOX5ALDH1A1 | |
| SCHEMBL18499709 | 0.84 | MT-CO2 (0.45) | ADAM17KMT2AMT-CO2ALOX5ALDH1A1 | |
| SCHEMBL18626054 | 0.83 | KMT2A (0.55) | KMT2AALDH1A1TP53MAPTHTT | |
| SCHEMBL18626051 | 0.83 | GAA (0.45) | ADAM17KMT2AMT-CO2ALOX5ALDH1A1 | |
| SCHEMBL20621743 | 0.80 | ADAM17 (0.61) | ADAM17KMT2A | |
| SCHEMBL20653913 | 0.77 | KMT2A (0.46) | KMT2AALDH1A1TP53MAPTHPGD | |
| SCHEMBL18499698 | 0.76 | MGLL (0.47) | ALDH1A1MAPTHPGDHTT | |
| SCHEMBL19156273 | 0.74 | KMT2A (0.44) | ADAM17KMT2AMT-CO2ALOX5ALDH1A1 | |
| SCHEMBL21549744 | 0.73 | MT-CO2 (0.42) | ADAM17KMT2AMT-CO2ALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| US-20220016261-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2022-01-20 | — | — | US | disclosed |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-05-13 | — | — | US | disclosed |
| US-20200306385-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-10-01 | — | — | US | disclosed |
| US-20190336614-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2019-11-07 | — | — | US | disclosed |
| US-20180125994-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
| US-9919056-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | ADC THERAPEUTICS S.A. (CH) | 2018-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | CD22, CD2, CD2BP2 | ADAM17 692/4885KMT2A 427/4885MT-CO2 4302/4885 |
| US-20190336614-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | ADAM17 1373/4885KMT2A 2477/4885MT-CO2 4193/4885 |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | PSMA2, PSMA7, FOLH1 | ADAM17 951/4885KMT2A 1144/4885MT-CO2 4706/4885 |
| US-20200306385-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | CD22, CD2, CD2BP2 | ADAM17 692/4885KMT2A 427/4885MT-CO2 4302/4885 |
| US-20180125994-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | FOLH1, PSMA2, DNPEP | ADAM17 1402/4885KMT2A 844/4885MT-CO2 3873/4885 |
| US-20220016261-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | PDCD10, CD79B, SBDS | ADAM17 2335/4885KMT2A 1216/4885MT-CO2 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.